75 results about "Cartilage Matrix" patented technology

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention discloses a biphasic hydrogel scaffold of a bionic bone cartilage matrix as well as a preparation method and application of the biphasic hydrogel scaffold, and belongs to the technical field of tissue engineering. The biphasic hydrogel scaffold of the bionic bone cartilage matrix provided by the invention comprises a hard bone matrix phase and a cartilage matrix phase. Wherein hard chitosan hydrogel with a porous structure is used as a hard bone matrix phase, and soft chitosan hydrogel is used as a cartilage matrix phase. The biphase hydrogel with the asymmetric matrix stiffness and the biochemical microenvironment can effectively release active substances in a controlled mode, the release period exceeds 21 days, the time requirement for osteochondral repair is met, and lasting support is provided for proliferation and differentiation of cells. Meanwhile, the biphase hydrogel provided by the invention has good biological safety, two matrix phases have different mechanical properties, the biphase hydrogel adapts to in-vivo complex physiological and mechanical environments, the fate of stem cells can be directionally regulated and controlled, synchronous regeneration and repair of osteochondral tissues are realized, and the biphase hydrogel has a wide application prospect.

Aiming at the challenge of osteochondral defect repair, the invention provides a preparation method of a fiber-reinforced self-repairing hydrogel scaffold (SBPS). According to the method, phenylboronic acid modified sodium alginate, polyvinyl alcohol and fibroin nanofibers rich in beta-Sheet are utilized to form the hydrogel through dynamic boric acid ester bonds and hydrogen bonds. The SBPS hydrogel loaded with PDGF-BB is combined with the nanosheet containing LDH / ChS / TGF-beta3, so that multi-dimensional synergy of mechanical strengthening, sequential drug release (PDGF-BB is released in an early stage and TGF-beta3 / Mg < 2 + > is released in a later stage), ROS removal and endogenous repair is realized. The Mg < 2 + > concentration gradient effect further assists staged regulation (vascularized bone regeneration-cartilage matrix synthesis), and breaks through the limitation of a single factor. Experiments prove that the scaffold can effectively drive angiogenesis, stem cell recruitment and cartilage / bone differentiation in vivo and in vitro, and finally osteochondral regeneration with structure-function matching is achieved.

The invention relates to the technical field of biomedical materials, and particularly discloses a preparation method of bionic hydrogel capable of bidirectionally inducing BMSCs (bone marrow mesenchymal stem cells) to promote epiphyseal plate repair through regulation and control mechanics, which comprises the following steps: step 1, mixing 10wt% of methacrylated gelatin, 10wt% of methacrylated decellularized cartilage matrix and 0.5 wt% of phenyl (2, 4, 6-trimethyl-1, 3-pentanediol) according to a ratio of the methacrylated gelatin to the methacrylated The preparation method comprises the following steps: respectively preparing methacrylated gelatin and methacrylated acellular cartilage matrix pre-polymerization solutions according to the concentration of (1, 2, 6-trimethylbenzoyl) lithium phosphate, and carrying out 37 DEG C constant-temperature dark water bath until the methacrylated gelatin and methacrylated acellular cartilage matrix pre-polymerization solutions are completely dissolved for later use; and 2, mixing the 10 wt% methacrylated decellularized cartilage matrix prepolymer solution and the 10 wt% methacrylated gelatin prepolymer solution according to a ratio of 3: 7 to obtain a methacrylated gelatin / methacrylated decellularized cartilage matrix prepolymer solution, carrying out cross-linking under blue light with a wavelength of 365 nm for 5-20 s, and carrying out drying to obtain the methacrylated gelatin / methacrylated decellularized cartilage matrix. The methylacryloylated gelatin / methylacryloylated acellular cartilage matrix composite hydrogel is prepared from the methylacryloylated gelatin and the methylacryloylated acellular cartilage matrix.

The present invention relates to the field of biomedical materials, and in particular to a method for preparing a decellularized cartilage matrix material derived from pig rib cartilage, comprising the following steps: (1) freezing and thawing the pig rib cartilage for 5 times; (2) soaking the pig rib cartilage frozen and thawed in step (1) in a sodium borohydride solution; (3) soaking the pig rib cartilage treated with sodium borohydride in step (2) in a sodium dodecyl sulfate solution; and (4) enzymolyzing the pig rib cartilage obtained in step (3) with a mixed solution of DNase and RNase. The present invention is suitable for decellularization of cartilage tissue with a thickness of 300 microns, and utilizes the spontaneous generation of hydrogen by the sodium borohydride solution to effectively expand the cartilage tissue, and then the surfactant SDS fully destroys the cell membrane, effectively removes the genetic material, and retains the effective components or extracellular matrix of the natural cartilage to the greatest extent.

The invention provides a nanogel for rapid permeation of articular cartilage and responsive release of a growth factor, which is prepared by polymerizing a peptide fragment which can be cut by a substance (mainly enzyme) which can be specifically expressed on the surface of osteoarthritis cells or secreted into a matrix with the growth factor, an acrylamide monomer and a cationic micromolecule monomer. Unreacted monomer molecules are filtered out through an ultrafiltration tube or other filtering systems, so that the nanogel which can rapidly permeate into the deep part of articular cartilage and can be recognized and cut by enzyme highly expressed on the surface of osteoarthritis cells or secreted enzyme to release growth factors is prepared, and the effect of the growth factors can be more effectively exerted; the nanogel has strong cartilage infiltration capacity, can completely infiltrate cartilage with the thickness of 1mm within less than 3 days, can be cut by MT1-MMP protein specifically expressed on the surfaces of osteoarthritis cells, releases growth factors, is specifically combined with growth factor receptors on the surfaces of cartilage cells, and activates downstream signal channels, so that the proliferation of the cartilage cells is promoted, and the cartilage cell proliferation rate is increased. The cartilage matrix secretion is promoted, so that the cartilage matrix thickening effect is realized, and the osteoarthritis is prevented and treated.

The invention belongs to the technical field of biological medicines, and particularly discloses application of ORM1 protein or VIM knockout adenovirus in preparation of a medicine for treating temporomandibular joint osteoarthritis (TMJOA). The invention proves that the expression of ORM1 is reduced in synovial fluid of a TMJOA patient and a unilateral anterior tooth reverse inhale model rat, and the degradation of cartilage matrix of the UAC rat can be remarkably inhibited and the progress of TMJOA can be relieved by locally injecting ORM1 protein. On the mechanism level, ORM1 is combined with waveform protein VIM to inhibit an MAPK channel, so that expression of MMP13 and MMP3 is reduced, cartilage matrix degradation is reduced, and cartilage steady state is maintained. In addition, the invention also finds that after the VIM of the rat is knocked out by using the adeno-associated virus, the progress of TMJOA, including cartilage degeneration and subchondral bone destruction, is also obviously improved. Therefore, the invention provides a new therapeutic target and a new therapeutic strategy for the TMJOA.

The gadolinium-based cationic polymer contrast agent is synthesized by chelating a cationic polymer and gadolinium ions, has high biological safety and can be used for cartilage imaging. The prepared contrast agent adopts an articular cavity direct injection method, so that the imaging effect is improved, and the contrast dosage is reduced. When the cartilage activity is normal, the content of glycosaminoglycan in the matrix is rich, and when the cartilage is inactivated or the activity is reduced, the content of glycosaminoglycan in the matrix is obviously reduced. The gadolinium-based cationic polymer contrast agent is combined with negatively charged glycosaminoglycan in a cartilage matrix through the charge effect. The gadolinium-based cationic polymer contrast agent can be used for noninvasive and quantitative evaluation of cartilage activity in nuclear magnetic resonance imaging, especially cartilage activity and stability in transplantation.

The invention provides a pharmaceutical composition for bone joints as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition is prepared from the following components in parts by weight: 20 to 2000 parts of N-acetylglucosamine and 10 to 1000 parts of non-denatured type II collagen. In the compound composition of the N-acetylglucosamine and the non-denatured type II collagen, the two core components play a complementary role: the N-acetylglucosamine is focused on promoting synthesis of a cartilage matrix and provides a material basis for cartilage repair; the non-denatured type II collagen reduces damage of autoimmune response to cartilage through immunoregulation, the non-denatured type II collagen and the non-denatured type II collagen have a synergistic effect, the symptoms such as arthralgia and swelling can be relieved, the joint structure can be improved from the double angles of repairing and protecting, and particularly the treatment effect on patients with severe osteoarthritis is remarkably superior to that of a single-component preparation; and an innovative and efficient choice is provided for the treatment of osteoarticular diseases.

The invention provides application of apoptotic cell pretreated macrophages in preparation of an osteoarthritis treatment preparation, a cell preparation and a preparation method, and relates to the technical field of biomedicine.In the embodiment of the invention, based on a mouse development model and an osteoarthritis (OA) model, it is found that in the area away from the cartilage surface, the apoptotic cell pretreated macrophages are subjected to apoptotic cell pretreatment, and the apoptotic cell pretreated macrophages are subjected to apoptotic cell pretreatment in the area away from the cartilage surface; in the macrophages, the content of the interment-related LAMP1 protein is obviously higher than that of the macrophages close to the cartilage surface area, and the expression results of TGF-beta 1 and LRG1 are respectively opposite and consistent with those of the LAMP1. The invention also finds that after the chemotactic effect of apoptotic cells on macrophages is weakened, the cellular burial effect is limited, and the cartilage matrix development disorder is caused. Based on development process inspiration, the invention provides a treatment strategy: bone marrow-derived macrophages pretreated by apoptotic cells are injected into articular cavities, and a good cartilage regeneration treatment effect can be achieved in a mouse arthritis model. In addition, the bone marrow-derived macrophages pretreated by apoptotic cells can still express TGF-beta1 after being injected into the body for 3 days, so that the effect of continuously promoting cartilage regeneration is achieved.

The invention relates to the technical field of medicines, and provides application of pulsatilla saponin B4 in preparation of a medicine for treating osteoarthritis. The pulsatilla saponin B4 can obviously promote the expression of SOX9, which is an important cartilage specific transcription factor, and inhibit the expression of matrix metalloproteinase 13 and disintegrin and metalloproteinase 5 with platelet reaction protein motifs at the same time, thereby finally relieving the degradation of extracellular cartilage matrixes such as II-type collagen and aggregation proteoglycan. Therefore, the pulsatilla saponin B4 can inhibit cartilage degeneration and improve cartilage extracellular matrix metabolic disorder. After the pulsatilla saponin B4 is injected into the abdominal cavity of a mouse with osteoarthritis, the progress of the osteoarthritis is effectively relieved, the side effect is relatively small, and no obvious injury is caused to main organs. The pulsatilla saponin B4 is applied to treatment of osteoarthritis, new application of the pulsatilla saponin B4 is developed, and a new choice is provided for preparation of the medicine for treating osteoarthritis.

The invention discloses a parasitic loranthus exosome-like nano vesicle and application thereof in preparation of a medicine for treating temporomandibular joint osteoarthritis. The taxillus sutchuenensis exosome-like nano-vesicles are prepared by combining a differential ultracentrifugation method with an ultrafiltration method. Researches show that the taxillus sutchuenensis exosome-like nano-vesicles can treat temporomandibular joint osteoarthritis through the following aspects: 1) an anti-inflammatory function: effectively reducing expression of inflammatory factors; 2) a cartilage degeneration inhibition function: blocking a cartilage matrix degradation pathway, and slowing down cartilage tissue damage; the taxillus sutchuenensis exosome-like nano-vesicles have the advantages that the taxillus sutchuenensis exosome-like nano-vesicles have obvious protection and repair effects on relieving temporal-mandibular joint osteoarthritis related bone and cartilage damage, and accordingly the taxillus sutchuenensis exosome-like nano-vesicles have good application prospects.

A method for modeling temporomandibular joint osteoarthritis, 6-week-old rats are selected, the rats are confirmed to have entered an anesthetized state before surgery, the rat's mandibular incisors are first checked and confirmed to be normal, the first arm of the device is sleeved on one side of the mandibular incisor, and the palatal side of the maxillary incisor is made to touch the slope surface of the second arm of the device, the device is checked and confirmed to not affect the rat's mandibular movement and occlusion, not significantly raise the bite, have no early contact, and the upper and lower jaw relationship is relatively stable; the device and the mandibular incisor sleeved with the device are fixed; then the rat is put back into the cage, and soft food or powdered feed is given after waking up; the device is removed after being fed for 8 weeks or more. It is verified that the condylar process of the rat changes significantly, the overall condylar process is significantly reduced, the subchondral bone is destroyed, and the expression of the cartilage matrix is also reduced. Thus, a TMJOA rat model exhibiting mandibular retrusion is formed.

The present invention relates to novel pharmaceutical compositions comprising GLP-1 and GLP-1 analogues inducing an anabolic stimulation of chondrocytes and a decreasing in chondrocyte catabolic including a decrease in cartilage matrix loss and cartilage degeneration for use in the treatment of cartilage disease. Composition according to the present invention induces cartilage regeneration and anabolic stimulation of chondrocytes, including chondrocyte proliferation and / or stem cell differentiation into chondrocytes.

The present invention provides a cartilage matrix having a high decellularization level and a low glycosaminoglycan (GAG) content. The cartilage matrix exhibits desirable characteristics, for example, cohesiveness, tackiness and malleability, for use in cartilage repair. Also provided is a method of preparing the cartilage matrix, comprising decellularizing a cartilage to generate a decellularized cartilage, and deglycosylating the decellularized cartilage.

The invention discloses application of rebaudioside B in preparation of a medicine for preventing and treating metabolism-related osteoarthritis, and belongs to the technical field of biological medicine. Animal experiments prove that the application of the natural micromolecular monomer rebaudioside B in preventing and treating osteoarthritis induced by high fat diet shows that the rebaudioside B can realize a cartilage protection effect by improving lipid deposition, regulating inflammatory response and promoting cartilage matrix synthesis; the method is suitable for intervention and prevention and treatment of metabolism-related osteoarticular diseases. The invention provides a set of intervention scheme with clear structure, multi-target action, clear mechanism and controllable path for the prevention and treatment of metabolism-related osteoarthritis, and provides a scientific basis for the application of rebaudioside B in the prevention and treatment of metabolism-related osteoarthritis.

An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine. A joint function-improving composition containing bacterial cells and / or a culture of a bacterium belonging to genera Lactobacillus, Lactococcus, Streptococcus or Bifidobacterium and a joint function-improving agent, a joint function-improving food or drink, a joint function-improving nutritional composition, joint function-improving feed or a joint function-improving pharmaceutical agent which is characterized by containing the joint function-improving composition.

The present invention discloses a method for delivering siMMP13 to chondrocytes by targeting peptide-modified Expi293 cell exosomes, comprising the following steps: separating and purifying Expi293 cell exosomes, labeling Expi293 cell exosomes, coupling DSPE-CAP polypeptide with Expi293 cell exosomes in a targeted manner, and then loading siMMP13 into the targeted modified Expi293 cell exosomes by electroporation. The present invention targets and modifies Expi293 cell exosomes to deliver siMMP13 through a chemical modification scheme, has a simple preparation method, high targeting, good aggregation effect at damaged parts, and realizes efficient drug release. Targeted delivery of siMMP13 can inhibit the metabolic decomposition of cartilage matrix, thereby inhibiting the progression of osteoarthritis, and is a drug delivery system with high safety, high targeting, and a wide range of applications.

The invention discloses a preparation method of biological glue with a layer-by-layer progressive function, which comprises the following steps: 1) uniformly mixing a silk fibroin solution and tadpole-shaped silk fibroin particles, adding a tannic acid solution, and mixing to form a viscous gel material; and 2) adding a cartilage matrix material / bone repair material into the viscous gel material prepared in the step 1), and uniformly mixing to obtain the biological glue. According to the invention, a reactant formed by the silk fibroin and the tannic acid has strong adhesion in an articular cavity wetting state, and rapid adhesion is realized; meanwhile, a viscous gel material formed by the silk fibroin, the tannic acid and the tadpole-shaped silk fibroin particles provides a three-dimensional environment for cell proliferation, so that the functions of adhesion, migration, differentiation, proliferation and the like of related cells are collected favorably, and the extrinsic repair effect of cartilage is realized; the biological glue is mainly used in the field of osteochondral injury repair, and the function of repairing osteochondral layer by layer is realized by adopting a layer-by-layer injection and rapid adhesion technology.

The invention belongs to the technical field of biological medicine, and discloses application of miRNA Let-7a-5p in a medicine for promoting cartilage formation, the invention provides the effect of miRNA let-7a-5p in cartilage formation / generation for the first time, and experiments prove that miRNA let-7a-5p can remarkably promote cartilage cell proliferation, enhance the activity of cartilage cells and remarkably improve matrix secretion of cartilage cells, so that the effect of promoting cartilage formation / generation is achieved. The expression of type II collagen is increased (the type II collagen is the main component of the cartilage matrix). Meanwhile, the miRNA let-7a-5p can also regulate other genes (such as NBL1 and DUSP7 genes) to inhibit cartilage ossification, and is expected to be applied to cartilage injury repair and osteoarthritis treatment, cartilage regeneration promotion and cartilage injury repair.

The present disclosure relates to a method of treating arthritis by targeting Tankyrase. The methods according to the present disclosure can be advantageously used for regeneration of cartilage tissue and for treating osteoarthritis by maximizing the matrix synthesis in cartilage by inhibition of Tankyrase and regulation of other proteins related therewith.

The application discloses a kind of for repairing cartilage decellularized cartilage matrix support and apoptotic corpuscle composition and its preparation method, composition includes: microporous support, support includes decellularized cartilage outer matrix and crosslinked organic polymer;Apoptotic corpuscle, apoptotic corpuscle exists in microporous support;Wherein, based on the volume 3.14mm 3 Microporous support, 0.01-0.02ug of apoptotic corpuscle is included.The combined support of the application can improve the activity of apoptotic corpuscle, prolong the action time of apoptotic corpuscle, achieve the effect of slow release, also can regulate joint cavity microenvironment, effectively promote joint cartilage repair, improve the repair effect of loss cartilage, avoid the security risks brought by traditional exogenous cell transplantation.

The application relates to an anti-inflammatory and cartilage regeneration promoting material, a preparation method and application thereof, and belongs to the technical field of biomedical materials. The anti-inflammatory and cartilage regeneration promoting material comprises a PLGA (50:50) polymer material, and a huperzine A derivative dimer loaded on the PLGA (50:50) polymer material through 3D printing. The application also provides the use of the anti-inflammatory and cartilage regeneration promoting material in the preparation of anti-inflammatory, cartilage protection or cartilage regeneration promoting drugs. The PLGA / A10E scaffold has good biocompatibility, the PLGA / A10E scaffold degradation release liquid can effectively promote the differentiation of cartilage precursor cells into cartilage, and increase the formation of cartilage collagen matrix and cartilage proteoglycan. The in-vitro degradation liquid of the PLGA / A10E scaffold can promote the expression of SOX9 under non-inflammatory conditions; under LPS-mediated inflammatory conditions, the expression of MMP-13 can be inhibited, thereby promoting the synthesis of cartilage matrix and inhibiting the degradation of cartilage matrix.

A pharmaceutical compositions includes GLP-1 and GLP-1 analogues inducing an anabolic stimulation of chondrocytes and a decreasing in chondrocyte catabolic including a decrease in cartilage matrix loss and cartilage degeneration for use in the treatment of cartilage disease. The composition induces cartilage regeneration and anabolic stimulation of chondrocytes, including chondrocyte proliferation and / or stem cell differentiation into chondrocytes.

The invention discloses a mesenchymal stem cell compound preparation for treating cartilage injury, and belongs to the technical field of cell biology. The composite preparation consists of human umbilical cord mesenchymal stem cells (hUC-MSC) subjected to specific pretreatment and a pharmaceutical carrier. The pretreatment method sequentially comprises the following steps: carrying out low-oxygen pretreatment on the hUC-MSC; then, carrying out pretreatment on a ferroptosis inhibitor Ferrostatin-1 under a low-oxygen condition; and finally, carrying out icariin pretreatment under a normal oxygen condition. The unique triple pretreatment strategy generates a remarkable synergistic effect, and can greatly improve the survival rate and the function maintenance capability of the hUC-MSC in the cartilage injury inflammatory microenvironment. Experimental results prove that the preparation can significantly inhibit collagen degradation and promote cartilage matrix regeneration, and the treatment efficiency of stem cell transplantation and the repair effect of cartilage injury are effectively improved.

The invention provides injectable hyaluronic acid hydrogel based on dynamic chemical bonds as well as a preparation method, application and a sol-gel conversion method of the injectable hyaluronic acid hydrogel, and belongs to the technical field of hydrogel. The preparation method comprises the following steps: oxidizing and modifying hyaluronic acid by adopting sodium periodate to obtain formylation modified hyaluronic acid, and carrying out Schiff base reaction on 3, 3 '-dithiodipropionyl hydrazine serving as a cross-linking agent and the formylation modified hyaluronic acid to prepare the injectable hyaluronic acid hydrogel. The HA-SS hydrogel provided by the invention not only has controllable gelation time, but also has excellent deformation resilience, elastic property and good biocompatibility, and can effectively simulate the structure and function of proteoglycan in a cartilage matrix. Due to the existence of the acylhydrazone bond and the disulfide bond, the injectable hyaluronic acid hydrogel based on the dynamic chemical bond has good rapid self-healing and pH / redox dual response performance.

The invention relates to the technical field of gene engineering, particularly discloses application of an NSUN2 gene in preparation of a product for diagnosing or treating osteoarthritis, and has the technical key points that the invention reveals that the NSUN2 has a potential value of serving as a clinical diagnosis biomarker; meanwhile, by knockdown and overexpression of the NSUN2 and detection of senescence and cartilage matrix synthesis and catabolism related indexes in cartilage cells, the invention finds that the NSUN2 can inhibit synthesis and secretion of cartilage matrix and promote cartilage senescence, and the increase of the NSUN2 is an important factor causing osteoarthritis, which indicates that the NSUN2 is expected to be used as a target to treat osteoarthritis.

The invention provides a tribenzoyl substituted vakognavine type diterpenoid alkaloid, a preparation method and application of the tribenzoyl substituted vakognavine type diterpenoid alkaloid, and a pharmaceutical composition. After rats are treated by the tribenzoyl substituted vakognavine type diterpenoid alkaloid provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

This invention provides a stress-triggered selective targeting hydrogel microsphere, its preparation method, and its application, belonging to the field of biomedical technology. The core of this invention is the "stress-triggered charge reversal" mechanism. It utilizes the interaction between weakly cross-linked disulfide bonds broken under stress and "charge reversal" messenger molecules to achieve "charge reversal" of nanoparticles under stress. A dual-network hydrogel microsphere system is prepared using microfluidic technology to achieve bearing lubrication and stress relaxation within the joint cavity. Stress-triggered charge reversal is achieved at stress-overloaded cartilage lesions, imparting a positive charge to the drug-loaded nanoparticles within the hydrogel microspheres. This significantly enhances the ability of the drug-loaded nanoparticles to penetrate deep into the cartilage matrix and target chondrocytes for drug release under the guidance of the charge. This enables the selective and targeted release of appropriate drug concentrations to deep-seated chondrocytes in pathological microenvironments induced by different stress intensities, achieving highly effective and low-toxicity treatment of osteoarthritis.

The invention discloses an antler plate oligopeptide as well as a preparation method and application thereof, and relates to the technical field of bioactive peptides. The preparation method comprises the following steps: extracting an antler plate protein crude extract by taking antler plates as a raw material, preparing short peptides with antler plate molecular weight of less than 3k through pepsin and trypsin hydrolysis, and performing Sephadex G-15 gel chromatography to obtain the antler plate short peptides. The prepared antler plate oligopeptide is low in molecular weight and high in hydrophobicity, easily penetrates through a biological membrane barrier to reach an in-vivo effective part, fully plays the biological activity effect of small molecule peptide, can effectively promote C28 / I2 cartilage cell proliferation, can increase the expression of osteoarthritis related phenotype protein Collagen II in an in-vitro model, can reduce the expression of MMP3, MMP13 and ADAMTS-5, and can be used for treating osteoarthritis. Meanwhile, cartilage matrix degradation in an osteoarthritis rat model is inhibited, cartilage injury is improved, and inflammatory response induced by osteoarthritis is reduced.